Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,823 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,205 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 10 | Abivax S.A.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05273554 | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07845266 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 13 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | completed | Phase 1 / Phase 2 | 393 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | completed | Phase 1 / Phase 2 | 263 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03674073 | A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | completed | Phase 1 | 24 | Chinese PLA General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT01791478 | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 1 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02217956 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma(CHIPASTIN) | completed | Phase 1 | 30 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04522336 | Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer | completed | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04104139 | TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer | completed | Phase 1 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03410030 | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)(AA NABPLAGEM) | completed | Phase 1 / Phase 2 | 17 | HonorHealth Research InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03586661 | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05034627 | Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 15 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT04037254 | Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring | completed | Phase 1 / Phase 2 | 22 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06464965 | Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer | completed | Phase 1 | 9 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04106856 | Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer(SHAPER) | completed | Phase 1 | 22 | University of UtahOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06745804 | Study of 68Ga-R10602 | completed | Phase 1 | 27 | Radionetics OncologyINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma(PRIME-HCC) | completed | Phase 1 / Phase 2 | 33 | Imperial College LondonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT03294083 | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | SillaJen, Inc.INDUSTRY | 3 | Jun 18, 2026 | clinicaltrials |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | completed | Phase 1 | 39 | AdaptimmuneINDUSTRY | 4 | Jun 17, 2026 | clinicaltrials |
| NCT03269526 | BATs Treatment for Pancreatic Cancer, Phase Ib/II | completed | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04495257 | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | completed | Phase 1 | 26 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05773105 | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | completed | Phase 1 / Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 | 273 | Genentech, Inc.INDUSTRY | 8 | Jun 8, 2026 | clinicaltrials |
| NCT02048150 | Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05181462 | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.(TRIFOUR) | completed | Phase 1 / Phase 2 | 117 | Cantargia ABINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06266143 | A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 71 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04846920 | A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018) | completed | Phase 1 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT05900986 | LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Integro TheranosticsINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT00911118 | Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer | completed | Phase 1 | 120 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT01334073 | Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors(EVAX) | completed | Phase 1 | 19 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT03851237 | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy | completed | Phase 1 | 69 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT02535533 | SLM + Axitinib for Clear Cell RCC | completed | Phase 1 / Phase 2 | 45 | Mohammed MilhemOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04358185 | Itacitinib in Advanced Hepatocellular Carcinoma(JAKaL) | completed | Phase 1 | 19 | Imperial College LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | completed | Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06059014 | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer(PRadR) | completed | Phase 1 / Phase 2 | 6 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials